Boone Capital Management LLC Buys Shares of 398,482 Tyra Biosciences, Inc. $TYRA

Boone Capital Management LLC bought a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 398,482 shares of the company’s stock, valued at approximately $10,476,000. Tyra Biosciences accounts for 3.5% of Boone Capital Management LLC’s investment portfolio, making the stock its 13th largest position. Boone Capital Management LLC owned 0.75% of Tyra Biosciences at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Commodore Capital LP boosted its stake in Tyra Biosciences by 8.9% during the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock valued at $47,216,000 after purchasing an additional 275,000 shares during the period. Farallon Capital Management LLC boosted its stake in Tyra Biosciences by 80.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after purchasing an additional 923,000 shares during the period. Vanguard Group Inc. lifted its stake in shares of Tyra Biosciences by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after acquiring an additional 118,492 shares during the period. 5AM Venture Management LLC lifted its stake in shares of Tyra Biosciences by 9.6% in the 4th quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock worth $27,060,000 after acquiring an additional 90,000 shares during the period. Finally, Caligan Partners LP lifted its stake in shares of Tyra Biosciences by 35.5% in the 4th quarter. Caligan Partners LP now owns 944,257 shares of the company’s stock worth $24,825,000 after acquiring an additional 247,432 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Gilla Kaplan sold 14,295 shares of the stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the sale, the director directly owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TYRA. JonesTrading began coverage on shares of Tyra Biosciences in a research note on Wednesday. They issued a “buy” rating and a $56.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a research note on Thursday, May 14th. Cantor Fitzgerald began coverage on shares of Tyra Biosciences in a research note on Tuesday, February 24th. They issued an “overweight” rating for the company. Finally, Piper Sandler upped their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $47.00.

Tyra Biosciences Price Performance

TYRA stock opened at $29.07 on Thursday. Tyra Biosciences, Inc. has a 12 month low of $8.98 and a 12 month high of $40.65. The firm has a market cap of $1.73 billion, a PE ratio of -13.33 and a beta of 0.75. The firm has a 50 day simple moving average of $33.04 and a 200 day simple moving average of $31.20.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). As a group, sell-side analysts expect that Tyra Biosciences, Inc. will post -2.69 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.